Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis

Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis - Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005381

Enrollment

Registered

2011-04-07

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer with liver metastasis

Interventions

day1:CPT-11(150mg/m2),L-OHP(65mg/m2),L-LV(200mg/m2) day1-2:5-FU(3200mg/m2)48hr civ, day1:Panitumumab(6mg/kg) or day1 and 7 cetuximab(400mg/m2) ever 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)histlogically colorectal adenocarcinoma and KRAS mutation status was wildtype 2)without primary surgery chemotherapy radiotherapy 3)within liver metastasis 4)a)age 20- b)PS(ECOG)0-1 c)without interstitinal lung fibrosis d)adequate organ function,14 days before entry hemoglobin:>9.0g/dl leukocyte count:>3000-12000/mm3 neutrophl cell count:>1500/mm3 serum bilirubin level <1.5mg/dl AST,ALT:<200U/I serum creatinine level:<1.2mg/dl estimate creatinine clearance level:>60ml/min nomal ECG within 28days before entry 5)written informed consent from patients

Exclusion criteria

Exclusion criteria: 1)had a previous serious medical illness or allergy for drugs 2)had active double cancer 3)had a hypersensitivity or taboo for test drugs 4)had active infection disease(oner 38.0C fever) 5)had serious complication(ireus,renal function,liver function,heart failure,diabetes within could not control) 6)had serious bowel blockage 7)had serious interstitinal fibrosis 8)had pleural effusion or abdominal dropsy within could not control 9)had watersolubility diarrhea 10)had brain metastasis 11)pregnant or lactating woman,woman who are capable of pregnancy or intend to get pregnant,man who are not inend to contraception 12)had mental illness 13)expect referred to above physician in charge of this trial gave a diagnosis the patient who can not join this trial for the safety

Design outcomes

Primary

Measure	Time frame
R0 rejective rate	—

Secondary

Measure	Time frame
Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026